China Machine-Building International Corp engages in various projects including tendering, machinery metallurgy, construction materials, power generation, and environmental protection. Self-described as involved in foreign aid and labor cooperation.

China Machine-Building International Corp

Biotechnology Research

CMIC, Inc.

Pharmaceutical Manufacturing

CMIC CMO USA

CMIC Group | 7,560 followers on LinkedIn. More than 80% of new drug development in Japan is supported by CMIC&#39;S efforts. 

実は、日本の新薬誕生の約8割に、私たちシミックの力が活かされています。 | Voted Best Contract Research Organization (CRO) 2024 by Citeline

CMIC Group was the first company to provide CRO (contract research organization) services in Japan. Relevant laws and rules had not been established when the group was first established. The CRO Study Group (which later became the Japan CRO Association) was formed by Mr.

Open "We"nnovation Facilitator, CEO Office, CMIC Group /【公式】Linkedinクリエイター

Shin Yamamoto

CHROMATOGRAPHY TECHNICAL SUPERVISOR

Bibin H.

Travel Specialist

CMIC Travel

President CMIC, Inc.

Robert Wetmore

CMIC Group

We are pleased to announce that CMIC Group has been recognized as the Best Contract Research Organization (CRO) at the 2024 Citeline Japan Awards! This award underscores our unwavering commitment to excellence and innovation in the field of clinical research. We extend our gratitude to our dedicated team and valued partners whose efforts have made this achievement possible. As a leading CRO in Japan, we remain focused on delivering high-quality, efficient solutions to meet the evolving needs of the pharmaceutical and biotech industries. To learn more about our services and how we can support your research initiatives, visit our website: https://en.cmicgroup.com/ #CMIC #CRO #ClinicalResearch #Citeline

From regulatory insights to strategic benefits, learn why Pharma and Biotech companies are interested in APAC for their drug development journey with Kento Nakamura . #Asia #Pharma #Biotech #CRO #DrugDevelopment

CMIC was honored to be part of the PBSS International Pharmaceutical and Bioscience Society Workshop in the San Francisco Bay Area last week! Valerie Leesch , Associate Director of Large Molecules, presented on “Biomarker Comparison – MSD Multiplex vs. Gyrolab” during the event. Her session provided critical insights into bioanalytical approaches for biologics and cell/gene therapy products, reinforcing CMIC’s commitment to advancing innovation in this space. Couldn't make it to the session? Visit our website for more insights and bioanalysis solutions: https://lnkd.in/eiiQ9F9r #Bioanalysis #Biologics #GeneTherapy #CMIC #PBSS2024 #InnovationInScience

On November 11, Keiko Oishi, COO of CMIC Group, participated in the event “Navigating Biopharma Innovation Across the Pacific” hosted by the Japan Society of Northern California and the U.S. Embassy in Tokyo Japan . In this insightful panel discussion, Keiko shared her extensive experience on topics including the clinical trial landscape in Japan, how CMIC supports global companies entering the Japanese market, and the latest advancements in decentralized clinical trials (DCT). Following the seminar, CMIC hosted a reception where attendees had the chance to network and discuss collaborative opportunities for advancing biopharma innovation. Thank you to all who joined and contributed to such a successful event!

Meet CMIC Group at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 📍 Location: San Diego Convention Center 📅 Date: December 7-10, 2024 Join us in San Diego at the world’s largest gathering of hematology professionals! With over 18,000 members from nearly 100 countries, #ASH unites clinicians and scientists dedicated to advancing research and treatment for blood diseases. Connect with the CMIC team to learn more about our services and how we’re helping drive innovations in hematology. https://lnkd.in/eech5cwe American Society of Hematology

Tomorrow, learn how recent regulatory updates and pricing reforms are paving the way for faster, smoother drug development in Japan. 🔗 Register here: https://lnkd.in/eFY35eGd

🌟 Introducing CMIC Group’s Monthly LinkedIn Newsletter 🌟 We’re pleased to introduce CMIC Monthly Insights, designed to keep you informed on the latest developments across the pharmaceutical and biotech industries in Japan, the U.S., APAC, and beyond. Each month, we’ll share key insights, regulatory updates, and exclusive highlights from CMIC’s experts. In this inaugural issue, gain insights from Japan’s Drug Discovery Ecosystem Summit, explore updates on Japan’s recent drug pricing reforms, and learn more about our upcoming participation at the Endpoints Japan Biotech Event. Subscribe to the newsletter and receive each edition directly to your inbox. This is a complimentary resource, providing you with valuable perspectives to support your decision-making in global healthcare. #CMIC #Pharma #Biotech #DrugDevelopment #Healthcare #Japan #CRO #DrugDiscovery

CMIC, Inc. is a proud sponsor of the upcoming PBSS Pharmaceutical and Bioscience Society - San Francisco Bay workshop on “Current State of Bioanalysis for Biologics and Cell/Gene Therapy Products.” Join us on November 15th for an in-depth exploration of bioanalysis innovations, featuring leading industry experts. Valerie Leesch , Associate Director of Large Molecules, will present at 3 PM on “Biomarker Comparison – MSD Multiplex vs. Gyrolab,” sharing insights into these powerful bioanalytical platforms. Don’t miss out! 🗓 Date: November 15, 2024 🕒 Time: 8:45 AM - 5:20 PM (Pacific Time) 📍 Location: Crowne Plaza, Foster City, CA Register now to reserve your spot and connect with top industry professionals! PBSS International https://lnkd.in/ePUGqcx #Bioanalysis #Biologics #GeneTherapy #CMIC #Biomarker #PBSS

Join CMIC Group and industry leaders at the upcoming Endpoints News & NIKKEI virtual event, “Developing your new medicine in Japan faster,” on Thursday, November 14th from 11:00 AM - 1:00 PM ET! Discover how recent regulatory improvements and pricing reforms are making it easier and faster to develop and launch new medicines in Japan. We’re proud sponsors of the session: "Unlocking Japan: Navigating clinical trials and market potential for global biopharma" at 12:00 PM ET. This session will feature insights on Japan’s clinical trial landscape, recent trends, and opportunities for global pharma and biotech companies. Hear from Masako Aoyagi, Head of Project Management at CMIC, and other experts from leading clinical sites and global sponsors. They’ll dive into the latest data on Japan’s PMDA approval times, strategies for patient recruitment, and efficient trial start-up times comparable to the US, Australia, Korea, and Taiwan. Learn more and register today: https://lnkd.in/eFY35eGd #PMDA #MHLW #Japan #Enpoints #Clinical #CRO #sponsors

CMIC Group is proud to be named a finalist in Fierce Biotech 's 2024 Fierce CRO Awards in the "Leadership in Regulatory Compliance" category! The Fierce CRO Awards celebrate excellence across the CRO industry, and we’re honored to be recognized for our unwavering commitment to regulatory adherence on a global scale. With extensive expertise in guiding clients through complex regulatory landscapes, including our in-depth knowledge of Japan’s regulatory requirements, CMIC Group ensures safe, compliant, and effective clinical research outcomes worldwide. The winners in each category will be announced in early December. Learn more about the Fierce CRO awards: https://lnkd.in/dSnuCpcz #FierceCROAwards #FierceCRO #CMIC #Regulatory #Compliance #CRO

Metric
Company Name	China Machine-Building International Corp
Symbol
MSH ID	COM:CMIC:EN
Market	PRIVATE
Sector	Capital Goods & Industrials
Industry	Engineering and Construction
Country	CN
Stage
Employee Count
Website	en.cmic.com
LinkedIn	cmic-group
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	27.71K
Web Traffic Growth	1.20
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CMIC

COM:CMIC:EN

China Machine-Building International Corp

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue